Reported about 6 hours ago
Hims & Hers Health Inc. faces a critical test as its shares, which soared by 458% after entering the weight-loss market, drop sharply following FDA regulations affecting its sales of generic anti-obesity drugs. Analysts warn that while the company's strategy to personalize treatments may offer an advantage, the recent FDA ruling may reshape investor expectations ahead of its earnings report, with predictions suggesting a mixed outlook.
Source: YAHOO